Trial Profile

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel (G/NP) or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pamrevlumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Registrational; Therapeutic Use
Acronyms LAPIS
Sponsors FibroGen; Kyntra Bio

07 Jan 2026 According to FibroGen media release, FibroGen is now called as Kyntra Bio.
26 Aug 2024 Status changed from active, no longer recruiting to completed.
30 Jul 2024 Results published in a FibroGen media release,

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com